Executive Summary

MAIA Biotechnology, Inc. is a cutting-edge, early stage biotech company, dedicated to developing targeted cancer therapies with novel mechanisms of action that are intended to meaningfully improve and extend the lives of patients with cancer.  A privately-held company based in Chicago and Houston, MAIA is led by a passionate, principled and dynamic Management Team with significant drug development experience, committed to advancing promising agents into trials in humans in the next 3-5 years.

MAIA’s Strategy

MAIA’s Management Team has developed a thoughtful, yet aggressive, business strategy which was designed to advance a strong value proposition.  MAIA controls risk and enhances its opportunity for success by diversifying and generating a broad portfolio of assets with a variety of compounds with novel mechanisms of action which have potential activity in multiple tumor types.

FORWARD-LOOKING STATEMENTS